Proficio Capital Partners LLC Invests $4.22 Million in Hologic, Inc. (NASDAQ:HOLX)

Proficio Capital Partners LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 58,465 shares of the medical equipment provider's stock, valued at approximately $4,215,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. General Partner Inc. bought a new stake in shares of Hologic in the fourth quarter worth $26,000. Venturi Wealth Management LLC boosted its holdings in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. lifted its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the period. Finally, Smithfield Trust Co grew its holdings in shares of Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Up 0.8 %

Shares of NASDAQ:HOLX traded up $0.46 during midday trading on Friday, reaching $61.47. The company had a trading volume of 7,414,532 shares, compared to its average volume of 1,746,764. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The company has a fifty day simple moving average of $66.26 and a two-hundred day simple moving average of $74.19. The firm has a market cap of $13.79 billion, a price-to-earnings ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Remove Ads

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of analyst reports. BNP Paribas upgraded Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Raymond James reiterated an "outperform" rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Wolfe Research started coverage on shares of Hologic in a research report on Friday, December 13th. They issued a "peer perform" rating for the company. Finally, Evercore ISI reduced their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Hologic has an average rating of "Hold" and an average target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.